论文部分内容阅读
乳腺癌分子显像不断快速发展,得益于新的更特异的显像剂和显像仪器的发展。当前,18F-氟代脱氧葡萄糖(18F-FDG)仍然是最广泛使用的代谢显像剂,但许多针对细胞靶点的更具特异性的示踪剂在发展,如针对DNA复制反映细胞增殖的3’-脱氧-3’-18F-氟代胸苷(18F-FLT)、反映细胞凋亡和雌激素受体状况的99mTc-annexin V和18F-16α-氟雌二醇、针对HER-2／neu受体的基因工程抗体片段等。同机PET-CT的临床应用不断扩大,专门用于乳腺显像的PET及术中探测放射性强度、指导外科医生对转移淋巴结和恶性病灶准确采样的便携式正电子探测器也正投入研究和应用中。
The rapid development of molecular imaging of breast cancer, thanks to the development of new and more specific imaging agents and imaging equipment. Currently, 18F-fluorodeoxyglucose (18F-FDG) remains the most widely used metabolic imaging agent, but many more specific tracer targets for cellular targets are evolving, as is the case for DNA replication that reflects cell proliferation 3’-18F-fluorothymidine (18F-FLT), 99mTc-annexin V and 18F-16α-fluoroestradiol, reflecting apoptosis and estrogen receptor status, against HER-2 / neu receptor genetically engineered antibody fragments and so on. The same PET-CT clinical applications continue to expand, specifically for the PET imaging and breast imaging to detect radioactive intensity, to guide the surgeon to accurately collect metastatic lymph nodes and malignant lesions of portable positron-based detectors are also being put into research and application .